Physician profile
Joseph Wayne Morrello
NPI 1205063906
$2,805.65
in general payments reported to CMS, 2019-2025
30 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $347 · 2021: $752 · 2022: $614 · 2023: $270 · 2024: $194 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.08 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.47 | 2019-2022 | |
| Lilly USA, LLC | $298.93 | 2019-2024 | Jardiance, Trulicity, Mounjaro |
| Merck Sharp & Dohme LLC | $174.74 | 2019-2021 | |
| Amgen INC. | $143.64 | 2020-2025 | Evenity, Prolia |
| Novo Nordisk INC | $139.79 | 2019-2022 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $100.98 | 2019-2022 | |
| Glaxosmithkline, LLC. | $87.63 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $83.56 | 2019-2022 | |
| Dexcom, INC. | $79.98 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $60.69 | 2021-2022 | |
| Pfizer INC. | $58.31 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $54.75 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $47.10 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $44.48 | 2019-2021 | |
| Amarin Pharma, INC. | $35.10 | 2020-2021 | |
| Abbott Laboratories | $34.08 | 2021 | |
| Janssen Biotech, INC. | $32.47 | 2024 | Tremfya |
| Biohaven Pharmaceutical Holding Company LTD. | $28.33 | 2022 | |
| Sun Pharmaceutical Industries INC. | $27.80 | 2023 | Ilumya |
| Xeris Pharmaceuticals, INC. | $24.78 | 2023 | Keveyis |
| Biohaven Pharmaceuticals, INC. | $20.79 | 2021 | |
| Indivior INC. | $18.87 | 2022 | |
| Exact Sciences Corporation | $18.76 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $17.07 | 2020 | |
| Hologic Sales and Service, LLC | $16.12 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.04 | 2021 | |
| Genentech USA, INC. | $12.91 | 2019 | |
| Mylan Specialty L.P. | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Morrello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.